Temsirolimus
- Generic Name
- Temsirolimus
- Brand Names
- Torisel
- Drug Type
- Small Molecule
- Chemical Formula
- C56H87NO16
- CAS Number
- 162635-04-3
- Unique Ingredient Identifier
- 624KN6GM2T
- Background
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
- Indication
For the treatment of renal cell carcinoma (RCC). Also investigated for use/treatment in breast cancer, lymphoma (unspecified), rheumatoid arthritis, and multiple myeloma.
- Associated Conditions
- Advanced Renal Cell Carcinoma
- Associated Therapies
- -
Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 24
- Registration Number
- NCT01946529
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2013-07-18
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT01902160
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
- Conditions
- Interventions
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2015-04-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT01851408
Phase II Evaluating Efficacy of Temsirolimus in 2 Line Therapy for Patients With Advanced Bladder Cancer
- First Posted Date
- 2013-04-10
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Institut Bergonié
- Target Recruit Count
- 54
- Registration Number
- NCT01827943
- Locations
- 🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷Centre François Baclesse, Caen, France
🇫🇷Centre Léon Bérard, Lyon, France
Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- Puma Biotechnology, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT01827267
- Locations
- 🇺🇸
Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
- First Posted Date
- 2013-02-01
- Last Posted Date
- 2013-05-01
- Lead Sponsor
- Pfizer
- Registration Number
- NCT01781442
Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma
- First Posted Date
- 2013-01-14
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 73
- Registration Number
- NCT01767194
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males
- Conditions
- Interventions
- First Posted Date
- 2012-10-24
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Celgene
- Target Recruit Count
- 31
- Registration Number
- NCT01712828
- Locations
- 🇺🇸
Covance Clinical Research Unit Dallas, Dallas, Texas, United States
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
- First Posted Date
- 2012-09-19
- Last Posted Date
- 2020-12-07
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 29
- Registration Number
- NCT01687673
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸Robert H Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy
- First Posted Date
- 2012-07-20
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 280
- Registration Number
- NCT01646021
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.